NCT05826028View on ClinicalTrials.gov

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

CompletedOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

April 20, 2022

Conditions
Secondary Progressive Multiple Sclerosis
Trial Locations (2)

2050

Novartis Investigational Site, Camperdown

2065

Novartis Investigational Site, St Leonards

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY